VivoSeq
Oncology

Advanced Lung Cancer

2

Pipeline Programs↗

5

Active Trials↗

2

Companies Involved↗

Advanced Lung Cancer is an early-stage landscape with 2 programs across 2 companies. The most active players are BioNTech, Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BioNTech logo

BioNTech

2 programs

PreclinicalChia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical2

BNT324

BioNTech

BNT327

BioNTech

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

5

clinical trials

Not yet recruiting3 · 60%
Recruiting2 · 40%

Clinical Trials

Trial Activity

Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
Not yet recruiting·MMassachusetts General Hospital·Preclinical·NCT06791057·420 enrolled
A Pilot Study of the VosCryoTM Breathalyser in Lung Cancer
Not yet recruiting·SSheffield Teaching Hospitals NHS Foundation Trust·N/A·NCT07689968·24 enrolled
A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB6411 for Injection in Patients With Advanced Lung Cancer
Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Preclinical·NCT07367529·465 enrolled
A Single-Arm Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of GK01 Cell Injection in Participants With Advanced Lung Cancer
Not yet recruiting·BBeijing Geekgene Technology Co., LTD·Phase 1·NCT07673419·10 enrolled
A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer
Recruiting·BioNTech logoBioNTech·Preclinical·NCT06892548·594 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)